(Fighting against New Coronary Pneumonia) Wang Zhigang talks about the source of New Coronavirus: scientifically responding to common human threats is its sole purpose
China News Agency, Beijing, June 7 (Li Jingze) "The purpose of virus tracing is only one, that is, to scientifically respond to the common threat to humans, that is, the new crown virus." Wang Zhigang, Minister of Science and Technology of China, said on the 7th that virus tracing is a global technology The responsibility of the community is also an important component of the epidemic research activities.
The State Council Information Office of the People's Republic of China issued a white paper on "China Action Against New Coronary Pneumonia" on the 7th and held a press conference. A reporter asked at the meeting that the origin of the new coronavirus is a matter of great concern. How is China's investigation and research conducted in this regard? Will it consider cooperating with some foreign experts?
"We have paid great attention to this matter from the beginning, and have made arrangements." Wang Zhigang said that the traceability activity is a scientific activity involving multiple disciplines such as epidemiology and pathogenic biology. In addition, the traceability process has very strict logic and empirical requirements, and it is necessary to insist on relying on scientists, maintaining a scientific attitude, and applying scientific methods.
He pointed out that the main body of traceability work is scientists from universities and enterprises such as the Chinese Academy of Sciences and the Chinese Academy of Medical Sciences. They use pathogenic biology, molecular informatics and other scientific methods to carry out scientific traceability around animal traceability and crowd traceability.
Wang Zhigang emphasized that the purpose of virus tracing is only one, that is, to scientifically respond to the common threat to mankind, that is, the new coronavirus. On the one hand, this can prevent the recurrence of similar epidemics; on the other hand, it can help to formulate a scientific plan for prevention and control of epidemics and treatment of diseases.
According to him, as of the end of May, Chinese scientists had published 206 papers, foreign research teams also published 282 papers, and China and the United States, the United Kingdom and other foreign teams jointly published 19 papers related to traceability. The New Coronavirus Information Database, which is shared globally, has collected and shared 36,442 new Coronavirus gene sequences worldwide, including 18,967 high-quality viral sequences.
"But at the same time, we must also realize that virus tracing has always been a scientific problem in human history, especially for a new virus like the new coronavirus. Our knowledge is still very limited." Wang Zhigang said that the next step is to continue to rely on scientists, With a scientific attitude, more research on scientific methodology. At the same time, maintaining respect and awe for science makes the purpose of research more pure, that is, to respond to the common threat of human beings-new coronary pneumonia.
At the same time, Wang Zhigang also introduced China's work on the research and development of effective drugs for new coronary pneumonia. He said that in the early stage of the epidemic, more than 160 research institutions and enterprises in China participated in the emergency research of drug research and development. The "three drugs and three programs" were determined. Among them, the "three drugs" are the tests of the "old drugs and new uses" of the three drugs, and the "three drugs" are the combination of drugs and treatment programs.
He further introduced that in addition to "new use of old drugs", there are also some new breakthroughs in drug research and development. First, traditional Chinese medicine has played an important role; second, the combination of drug development and clinical treatment has made some progress; third, cross-disciplinary integration of different disciplines has played an important role; fourth, some special drugs have been developed at the same time.
He said that China is also actively sharing experience in drug development and clinical treatment for countries to choose according to their own situation. The Chinese research team has published several papers, shared scientific research results with more than 200 countries and regions, and also supported companies and clinical institutions to carry out international multi-center clinical trials.
Regarding the effects of the above drugs and treatment experience abroad, Wang Zhigang said that this mainly depends on how scientists and medical workers from various countries summarize and improve in clinical practice. (Finish)